Vicarious Surgical Finalizes Dissolution: Shareholders Approve Assignment for Benefit of Creditors, All Directors Resign, Stock Deregistration Imminent
RBOTW sits 67% above its 52-week low of $0.
Summary
Vicarious Surgical shareholders approved an assignment for the benefit of creditors and dissolution. The board executed the assignment, terminated executives, and all directors resigned. Stock deregistration is imminent, and stockholders are unlikely to receive any recovery.
Key Events · Legal and Risk Events · RBOTW
-
Shareholders Approve Dissolution
At a special meeting, 13,348,600 votes were cast in favor of an assignment for the benefit of creditors and voluntary dissolution, with only 100,879 against.
-
Assignment Agreement Executed
Substantially all assets were transferred to Vicarious Liquidation, LLC, an assignee for the benefit of creditors, with creditors having priority over stockholders.
-
Entire Board Resigns
All seven directors resigned effective upon the filing of Form 15 to deregister the company's common stock.
-
Top Executives Terminated with Severance
CEO Stephen From, President Adam Sachs, CTO Sammy Khalifa, and CMO Dr. Barry Greene were terminated, with severance payments totaling over $2 million (From: $672,699; Sachs: $779,190; Khalifa: $611,261).
Analysis · RBOTW · Industrial Applications And Services
With shareholder approval now secured, Vicarious Surgical is transferring all assets to an assignee for the benefit of creditors and proceeding with voluntary dissolution. The board immediately authorized the assignment agreement and dissolution, terminated top executives—triggering over $2 million in severance—and all directors resigned. The company will file to deregister its stock, and stockholders are not expected to receive any distribution. This marks the end of the company as a going concern, wiping out equity value.
At the time of this filing, RBOTW was trading at $0.00 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $0.00 to $0.09. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.